1Blum J L,Jones S E,Bbzdar A U,et al.Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic Breat cancer[J].J Clin Oncol,1999,17:485-493.
3Gluck S,McKenna E F Jr,Royce M.XeNA:capecitabine plus docetaxel,with or without trastuzumab,as preoperative therapy for early breast cancer[J].Int J Med Sci,2008,5(6):341-346.
4Biganzoli L,Martin M,Twelves C.Moving forward with capecitabine:a glimpse of the future[J].Oncologist,2002,7(Supp16):29-35.
5Cieschke R,Reigner B,Blesch K S,et al.Population pharmacokinetic analysis of the major metabolites of capecitabine[J].J Pharmacokinet pharmacodyn,2002,29(1):25-47.
6Nole F,Catania C,Mandala M,et al.Fhase I study of vinrelbine(V) and capecitabine (C) in advanced breast cancer(A B C)[J].Brest Cancer Res Treat,2000,64:125.
二级参考文献2
1Hiroyuki Eda,Kaori Fujimoto,Shin-ichi Watanabe,Masako Ura,Ayako Hino,Yutaka Tanaka,Kenji Wada,Hideo Ishitsuka. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine[J] 1993,Cancer Chemotherapy and Pharmacology(5):333～338
